Medical news of portal is the most update information on pharmaceutical and medical equipment market



The periodical about the pharmaceutical and medical equipment markets


(Russian pharmacies) - specialized periodical edition for pgarmacy professionals


Medical Council - Scientific Journal for Physicians

Home / News


Biocad’s IL-17 inhibitor shows high efficacy in mid-stage trial

Russia’s leading biotech firm Biocad has analyzed results from its Phase II study in which the original Russian interleukin (IL)-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed positive results in the treatment of ankylosing spondylitis.

BCD-085 is an original monoclonal antibody drug blocking interleukin-17, a cytokine playing a key role in developing and maintaining various autoimmune and immuno-inflammatory diseases.

The worldwide prevalence of psoriasis and ankylosing spondylitis is high – about 4% of the world population. The majority of psoriasis patients have serious psychological problems due to social isolation, while patients with ankylosing spondylitis may rapidly become disabled if diagnosed late or treated inappropriately. Both diseases are a serious medical and social challenge, especially because they often affect young people of working age (22 to 35 years old). The European market of IL-17 inhibitors is over $700 million and it is expected to grow to $1,677 million within next five years. Biocad expects to gain an essential share of this market.

BCD-085 has demonstrated extremely high efficacy in the recently completed Phase II clinical study. Over the first three months of treatment with Interleukin-17 inhibitor at a dose of 120mg, significant clinical response (PASI 75) was achieved in 93% of patients with moderate to severe psoriasis who did not respond to conventional treatments. Similar improvements were seen in patients with ankylosing spondylitis who were treated with IL-17 inhibitor 120mg: 91% of patients demonstrated clinical improvements (ASAS20) after four months of treatment.

Оne-year treatment with this IL-17 inhibitor resulted in a sustained improvement in psoriasis symptoms (PASI 75) in 98% of cases, with over 50% of patients having an sPGA score of 0 or 1 at the end of the observation, which refers to almost complete skin clearance. High efficacy of BCD-085comes along with a favorable safety profile



Remedium group


publishing house


programmer of electronic software products


advertisement agency


rent-a-rep company